Antioxidant and antiprotease status in peripheral blood and BAL fluid after cardiopulmonary bypass.
OBJECTIVE
Cardiopulmonary bypass (CPB) triggers systemic inflammation. Recent evidence suggests that metabolic and oxygenation management can affect the outcome of patients after cardiac surgery. We investigated the influence of oxidant/antioxidant and protease/antiprotease imbalance during the course of systemic and pulmonary inflammation.


METHODS
In a study of 61 patients, we measured the intracellular thiol concentration, the intracellular activity of cathepsins and elastase, and the concentrations of secreted elastase, soluble alpha(1)-proteinase inhibitor (alpha(1)-PI), and secretory leukoprotease inhibitor (SLPI). Peripheral blood and BAL fluid (BALF) were obtained preoperatively and 2 h after CPB.


RESULTS
A post-CPB depletion of thiol was found in blood granulocytes, lymphocytes, and monocytes, as well as BALF lymphocytes and macrophages. The degree of postoperative depletion correlated with PO(2) and blood glucose levels during CPB. Concomitant reduction of FEV(1) showed positive correlation with thiol depletion of blood monocytes and granulocytes. Elastase and cathepsin activities were increased in blood cells but not in lymphocytes or macrophages from BALF. The concentrations of secreted elastase were significantly increased in blood plasma but not in BALF. Enhanced antiprotease (alpha(1)-PI, SLPI) concentrations were measured in BALF but not in peripheral blood.


CONCLUSIONS
The inflammatory response of the intra-alveolar compartment is clearly distinguishable from systemic inflammation. CPB causes a differentiated impairment of the antioxidant defense system as well as a protease/antiprotease imbalance in blood and BALF. Oxygenation under circumstances of CPB and concomitant pulmonary disease, as well as blood glucose metabolism, influence the antioxidative defense. Individual perioperative management of blood glucose and oxygenation could improve cellular defense systems in the peripheral blood and BALF and therefore result in a more favorable patient outcome.
Frass
O M
OM
Department of Cardiac and Thoracic Surgery, Otto-von-Guericke University, Magdeburg, Germany. oliver.frass@medizin.uni-magdeburg.de
Bühling
F
F
Täger
M
M
Frass
H
H
Ansorge
S
S
Huth
C
C
Welte
T
T
D000975:Antioxidants / Q000378:metabolism*; D001772:Blood Cell Count; D001786:Blood Glucose / Q000032:analysis; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry*; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass / Q000009:adverse effects; D002403:Cathepsins / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D010196:Pancreatic Elastase / Q000378:metabolism; D011480:Protease Inhibitors / Q000378:metabolism*; D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins / Q000378:metabolism; D053481:Secretory Leukocyte Peptidase Inhibitor; D013438:Sulfhydryl Compounds / Q000097:blood; D018746:Systemic Inflammatory Response Syndrome / Q000209:etiology / Q000378:metabolism; D000515:alpha 1-Antitrypsin / Q000378:metabolism
D000975:Antioxidants; D001786:Blood Glucose; D011480:Protease Inhibitors; D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins; C506814:SLPI protein, human; D053481:Secretory Leukocyte Peptidase Inhibitor; D013438:Sulfhydryl Compounds; D000515:alpha 1-Antitrypsin; D002403:Cathepsins; D010196:Pancreatic Elastase; D010100:Oxygen